Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 814-00646 MIDCAP FINANCIAL INVESTMENT CORPORATION (Exact name of Registrant as specified in its charter) | Maryland | 52-2439556 | | --- | --- | | (State or other ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 814-00646 MIDCAP FINANCIAL INVESTMENT CORPORATION (Exact name of Registrant as specified in its charter) | Maryland | 52-2439556 | | --- | --- | | (State or other ...

PACS Group, Inc. Reports Fiscal Year and Fourth Quarter 2025 Results Conference Call and Webcast Scheduled for Today, February 26, 2026, at 5:30 pm ET. SALT LAKE CITY, Utah, February 26, 2026 – PACS Group, Inc. (NYSE: PACS) ("PACS" or the "Company"), which together with its subsidiaries is one of the largest post-acute healthcare companies in the United States, announced operating results for the fiscal year and fourth quarter of 2025. Full Year 2025 Financial Highlights Fourth Quarter 2025 Financial Highli ...

Exhibit 99.1 Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update VANCOUVER, British Columbia and BOSTON, MA, Feb 26, 2026 – Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided a business update. "2025 marked a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. 000-26224 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 51-0317849 (STATE OR OTHER ...

Exhibit 99.01 Contacts: Investors Media Anne-Sophie Seigneurbieux Kali Fry Intuit Inc. Intuit Inc. 650-944-5655 650-944-3036 anne-sophie_seigneurbieux@intuit.com kali_fry@intuit.com Intuit Reports Strong Second-Quarter Results and Reiterates Full-Year Guidance Global Business Solutions Online Ecosystem Revenue Grew 21 percent; Consumer Revenue Grew 15 percent MOUNTAIN VIEW, Calif. - February 26, 2026 - Intuit Inc. (Nasdaq: INTU), the global financial technology platform that makes Intuit TurboTax, Credit Ka ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39394 Montrose Environmental Group, Inc. (Exact name of Registrant as specified in its Charter) Delaware 46-4195044 (State or other j ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _____________TO_____________ COMMISSION FILE NO.: 0-26823 ALLIANCE RESOURCE PARTNERS, L.P. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 7 ...

Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update • Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – Exhibit 99.1 NEW YORK, NY, February 26, 2026 (GLOBE NEWSWIRE) – Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today reported its financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. "We solidified our leaders ...

Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-point reflects 23% growth; Exhibit 99.1 Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, CO, February 26, 2026 – Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and oper ...